Search results for "Covid."

showing 10 items of 2543 documents

Mortality in COVID-19 disease patients: Correlating Association of Major histocompatibility complex (MHC) with severe acute respiratory syndrome 2 (S…

2020

Highlights • In addition to ethnicity, socio-economic factors, prior vaccinations and exposure to other coronaviruses, other factors need to be considered to explain geographical and regional variations in susceptibility, severity of clinical expression of COVID-19 disease and outcomes. • Differences in peptide binding of SARS-CoV-2 variants to MHC class II, but not to MHC class I alleles frequent in individuals with African, Asian or Caucasian descent could be identified. • Single mutations in the wildtype of SARS-CoV-2, the so called B strain or L strain impact on MHC presentation • Most likely there is selective pressure from MHC class II alleles in regard to binding of the ORF8 (L84S) v…

0301 basic medicinecross-reactivityMHC bindingPeptide bindingmedicine.disease_causeAutoimmunity0302 clinical medicine030212 general & internal medicineMutationepitopeautoimmunityGeneral MedicineHLAEuropeviral variantsInfectious DiseasesCoronavirus InfectionsPeptides ; COVID-19 ; Disease association ; Cross-reactivity ; MHC ; T-cells ; Autoimmunity ; Epitope ; Cytokines ; Viral variants ; HLA ; SARS ; SARS-CoV-2 ; MHC bindingMicrobiology (medical)Asia030106 microbiologyPneumonia ViralHuman leukocyte antigenBiologyMajor histocompatibility complexArticlelcsh:Infectious and parasitic diseases03 medical and health sciencesBetacoronavirusMHC class ImedicineHumanslcsh:RC109-216AllelePandemicsAllelesSARSMHC class IISARS-CoV-2T-cellsdisease associationHistocompatibility Antigens Class IHistocompatibility Antigens Class IICOVID-19cytokinesImmunologyAfricabiology.proteinpeptidesMHCInternational Journal of Infectious Diseases
researchProduct

Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia

2020

A coronavirus (HCoV-19) has caused the novel coronavirus disease (COVID-19) outbreak in Wuhan, China. Preventing and reversing the cytokine storm may be the key to save the patients with severe COVID-19 pneumonia. Mesenchymal stem cells (MSCs) have been shown to possess a comprehensive powerful immunomodulatory function. This study aims to investigate whether MSC transplantation improves the outcome of 7 enrolled patients with COVID-19 pneumonia in Beijing YouAn Hospital, China, from Jan 23, 2020 to Feb 16, 2020. The clinical outcomes, as well as changes of inflammatory and immune function levels and adverse effects of 7 enrolled patients were assessed for 14 days after MSC injection. MSCs …

0301 basic medicinefunction recoverymedicine.medical_specialtyPopulationimmunomodulationGastroenterologyPathology and Forensic MedicineImmunomodulation03 medical and health sciences0302 clinical medicineImmune systemInternal medicinemedicinecell transplantationAdverse effecteducationSettore MED/04 - Patologia Generalemesenchymal stem cellseducation.field_of_studybusiness.industryMesenchymal stem cellCOVID-19Cell Biologymedicine.diseaseFunction recoveryACE2 negativeTransplantationPneumonia030104 developmental biologyMesenchymal stem cellsNeurology (clinical)Cell transplantationGeriatrics and GerontologybusinessCytokine storm030217 neurology & neurosurgeryCD8Aging and disease
researchProduct

Implications of SARS-COV-2 infection in the diagnosis and management of the pediatric gastrointestinal disease

2021

AbstractGastrointestinal diseases such as celiac disease, functional gastrointestinal disorders (FGIDs), inflammatory bowel disease (IBDs) and acute or chronic diarrhea are quite frequent in the pediatric population. The approach, the diagnosis and management can be changed in the 2019 coronavirus disease (COVID-19) pandemic era. This review has focused on: i) the current understanding of digestive involvement in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected children and adolescents and the clinical implications of COVID-19 for pediatric gastroenterologists, ii) the impact of COVID-19 on the clinical approach to patients with pre-existing or onset diseases, including…

0301 basic medicinemedicine.medical_specialtyAdolescentGastrointestinal Diseasesmedicine.medical_treatmentFunctional gastrointestinal disordersACE2ReviewDiseaseChronic liver diseaseInflammatory bowel diseaseDigestive endoscopyPediatricsGastrointestinal symptomsInflammatory bowel disease03 medical and health sciencesLiver diseaseFunctional gastrointestinal disorder0302 clinical medicineACE2; COVID-19; Digestive endoscopy; Functional gastrointestinal disorders; Gastrointestinal symptoms; Inflammatory bowel disease; Liver disease; Pediatrics; Adolescent; COVID-19; Child; Gastrointestinal Diseases; Humans; Infection Control; SARS-CoV-2Gastrointestinal symptomPandemicmedicineHumansRisk factorIntensive care medicineChildInfection Controlbusiness.industrySARS-CoV-2lcsh:RJ1-570COVID-19lcsh:PediatricsImmunosuppressionmedicine.disease030104 developmental biologyGastrointestinal disease030211 gastroenterology & hepatologybusinessLiver disease
researchProduct

Characteristics and Outcomes of 35 Breast Cancer Patients Infected With COVID-19

2020

Since December 2019, a novel coronavirus disease (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly engulfed the world. Cancer patients infected with COVID-19 are considered to carry higher severity of the disease and higher mortality rate than common COVID-19 patients in previous studies. However, due to the poor clinical information on COVID-19 patients with cancer, the evidences that supported this conclusion are insufficient. At present, rather limited reports have analyzed the clinical data of breast cancer patients infected with COVID-19. Therefore, in this retrospective study, we described the clinical characteristics and the outcomes of 35 …

0301 basic medicinemedicine.medical_specialtyCancer ResearchCoronavirus disease 2019 (COVID-19)Diseasemedicine.disease_causelcsh:RC254-282Asymptomatic03 medical and health sciences0302 clinical medicineBreast cancerbreast cancerInternal medicineMedicineclinical characteristicsCoronavirusOriginal Researchnon-cancerbusiness.industrySARS-CoV-2Mortality rateCancerRetrospective cohort studylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.disease030104 developmental biologyOncology030220 oncology & carcinogenesisprognosismedicine.symptombusinessFrontiers in Oncology
researchProduct

Managing cancer patients during the COVID-19 pandemic:an ESMO multidisciplinary expert consensus

2020

We established an international consortium to review and discuss relevant clinical evidence in order to develop expert consensus statements related to cancer management during the severe acute respiratory syndrome coronavirus 2-related disease (COVID-19) pandemic. The steering committee prepared 10 working packages addressing significant clinical questions from diagnosis to surgery. During a virtual consensus meeting of 62 global experts and one patient advocate, led by the European Society for Medical Oncology, statements were discussed, amended and voted upon. When consensus could not be reached, the panel revised statements until a consensus was reached. Overall, the expert panel agreed …

0301 basic medicinemedicine.medical_specialtyConsensusCoronavirus disease 2019 (COVID-19)Settore MED/18 - CHIRURGIA GENERALEPneumonia ViraleducationDiseaseMedical OncologyReal-Time Polymerase Chain ReactionSpecial Article03 medical and health sciencesBetacoronavirus0302 clinical medicineMultidisciplinary approachNeoplasmsPandemicGranulocyte Colony-Stimulating FactorMedicineHumansDisease management (health)PandemicsSocieties Medicalbusiness.industrySARS-CoV-2Expert consensusCOVID-19Disease ManagementcovidHematologyTelemedicineEurope030104 developmental biologyOncology030220 oncology & carcinogenesisFamily medicineCancer managementSevere acute respiratory syndrome coronavirusbusinessCoronavirus InfectionsT-Lymphocytes Cytotoxic
researchProduct

The role of immunogenetics in covid‐19

2021

Coronavirus disease 2019 (COVID-19) is induced by SARS-CoV-2 and may arise as a variety of clinical manifestations, ranging from an asymptomatic condition to a life-threatening disease associated with cytokine storm, multiorgan and respiratory failure. The molecular mechanism behind such variability is still under investigation. Several pieces of experimental evidence suggest that genetic variants influencing the onset, maintenance and resolution of the immune response may be fundamental in predicting the evolution of the disease. The identification of genetic variants behind immune system reactivity and function in COVID-19 may help in the elaboration of personalized therapeutic strategies…

0301 basic medicinemedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)ReviewDiseaseImmunogeneticsHuman leukocyte antigenSeverity of Illness IndexCatalysisSARS‐CoV‐2ABO Blood-Group SystemInorganic Chemistrylcsh:Chemistry03 medical and health sciences0302 clinical medicineCOVID‐19HLA AntigensmedicineImmunogeneticsHumansGenetic Predisposition to DiseaseGenetic variabilityPhysical and Theoretical ChemistryIntensive care medicineMolecular Biologylcsh:QH301-705.5SpectroscopyAB0business.industrySARS-CoV-2Organic ChemistryImmunityCOVID-19General MedicineImmunosenescencemedicine.disease3. Good healthComputer Science ApplicationsKIRHLA030104 developmental biologylcsh:Biology (General)lcsh:QD1-999030220 oncology & carcinogenesisIdentification (biology)Disease SusceptibilityCytokine stormbusiness
researchProduct

What can visual caregivers expect with patients treated for SARS-CoV-2? An analysis of ongoing clinical trials and ocular side effects

2020

Within the COVID-19 pandemic context, the WHO has proposed a list of medicines to treat patients with severe acute respiratory syndrome (SARS-CoV-2). An analysis of their ocular side effects was performed. Only chloroquine and hydroxychloroquine were found to have an ocular impact in the medium and long-term. Detailed search strategies were performed in EMBASE, MEDLINE, SCOPUS and WOS Core Collection. Additionally, the worldwide ongoing clinical trials including chloroquine or hydroxychloroquine were evaluated, and their proposals of drug administration and exclusion criteria analyzed. In general, high maximum cumulative doses of chloroquine or hydroxychloroquine are being used for a short…

0301 basic medicinemedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsCoronavirus disease 2019 (COVID-19)Health PersonnelRetinal pathology / researchSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Context (language use)medicine.disease_causeRetinaAntimalarials03 medical and health sciences0302 clinical medicineRetinal DiseasesChloroquineInternal medicinePandemicmedicineHumansRETINARetina – medical therapiesCoronavirusPharmacologyOphthalmologistsSARS-CoV-2business.industryCOVID-19ChloroquineHydroxychloroquineGeneral MedicineSystemic drug retinal ToxicityTechniques of retinal examinationCOVID-19 Drug TreatmentCoronavirusClinical trialOphthalmology030104 developmental biologyCaregiversMedicina Preventiva y Salud Pública030221 ophthalmology & optometryHuman medicinebusinessHydroxychloroquinemedicine.drugEuropean journal of ophthalmology
researchProduct

Vaccination in multiple sclerosis patients treated with highly effective disease-modifying drugs: an overview with consideration of cladribine tablets

2021

Infectious diseases are an important consideration in autoimmune conditions such as multiple sclerosis. Infective episodes may trigger relapses and significantly deteriorate the course of the disease. Some immunotherapies may cause increased rates of infection-related adverse events. Thus, infection and vaccine-related issues should be included in the individualized patient-specific treatment strategy and counseling before starting therapy and regularly on treatment. Clinical and epidemiological studies as well as pharmacovigilance data repeatedly demonstrated the safety of the great majority of vaccines in multiple sclerosis patients. Moreover, studies have shown that vaccinations with kil…

0301 basic medicinemedicine.medical_specialtyMedizincladribine tabletsDiseaseReviewimmunizationmultiple sclerosis1117 Public Health and Health Services03 medical and health sciences0302 clinical medicineNatalizumabInternal medicinevaccinePharmacovigilancemedicineddc:610CladribineAdverse effectRC346-42911 Medical and Health SciencesPharmacologybusiness.industryMultiple sclerosisCOVID-19Vaccine efficacymedicine.diseaseVaccinationCoronavirus030104 developmental biologyNeurology1107 ImmunologyNeurology (clinical)Neurology. Diseases of the nervous systembusiness030217 neurology & neurosurgerymedicine.drugTherapeutic Advances in Neurological Disorders
researchProduct

Unraveling the thread of uncontrolled immune response in COVID-19 and STEMI: an emerging need for knowledge sharing

2021

The outbreak of severe acute respiratory syndrome coronavirus 2 that first emerged in Wuhan in December 2019 has resulted in the devastating pandemic of coronavirus disease 2019, creating an emerging need for knowledge sharing. Meanwhile, myocardial infarction is and will probably remain the foremost cause of death in the Western world throughout the coming decades. Severe deregulation of the immune system can unnecessarily expand the inflammatory response and participate in target and multiple organ failure, in infection but also in critical illness. Indeed, the course and fate of inflammatory cells observed in severe ST-elevation myocardial infarction (neutrophilia, monocytosis, and lymp…

0301 basic medicinemedicine.medical_specialtyPhysiologyReview030204 cardiovascular system & hematologycoronavirus disease 201903 medical and health sciences0302 clinical medicineImmune systemMonocytosisImmunityPhysiology (medical)PandemicHumansMedicineIntensive care medicineCause of deathInflammationInnate immune systembusiness.industryCOVID-19Acquired immune systemmedicine.diseaseimmunityKnowledge sharingmyocardial infarction030104 developmental biologyImmune SystemST Elevation Myocardial InfarctionCardiology and Cardiovascular MedicinebusinessAmerican Journal of Physiology-Heart and Circulatory Physiology
researchProduct

Protective Effects of Statins Administration in European and North American Patients Infected with COVID-19: A Meta-Analysis

2021

AbstractSevere acute respiratory syndrome coronavirus 2 has spread rapidly throughout the world, becoming an overwhelming global health emergency. The array of injuries caused by this virus is broad and not limited to the respiratory system, but encompassing also extensive endothelial and systemic tissue damage. Since statins effectively improve endothelial function, these drugs may have beneficial effects in patients with coronavirus disease 2019 (COVID-19). Therefore, this investigation aimed to provide an updated overview on the interplay between statins and COVID-19, with particular focus on their potentially protective role against progression toward severe or critical illness and deat…

0301 basic medicinemedicine.medical_specialtyStatinmedicine.drug_class030204 cardiovascular system & hematologyStatins COVID-19 Meta-analysislaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled triallawInternal medicinemedicineAdjuvant therapyGlobal healthHumansSARS-CoV-2business.industryStatinsCOVID-19HematologyOdds ratioUnited StatesConfidence intervalCOVID-19 Drug TreatmentReview articleEuropeHospitalizationMeta-analysis030104 developmental biologyMeta-analysisHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessSeminars in Thrombosis and Hemostasis
researchProduct